Cancer as a Risk Factor for Cardiovascular Disease

被引：0
作者：
Dana Elena Giza
Gloria Iliescu
Saamir Hassan
Konstantinos Marmagkiolis
Cezar Iliescu
机构：
[1] The University of Texas MD Anderson Cancer Center,Department of Cardiology
[2] The University of Texas MD Anderson Cancer Center,Department of General Internal Medicine, Division of Internal Medicine
[3] Citizens Memorial Hospital,Heart and Vascular Institute
[4] University of Missouri,undefined
来源：
Current Oncology Reports | 2017年 / 19卷
关键词：
Cardiovascular disease; Risk factors; Cancer; Cardiotoxicity; Radiation; Atherosclerosis; Anthracyclines; Cardiac biomarkers; LVEF;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
Improvements in early diagnosis and cancer treatments have contributed to high survival rates for many cancer patients. However, these patients often die of cardiovascular disease rather than recurrence of their cancer. Heart disease manifesting after cancer may be due to several mechanisms: shared cardiovascular risks between cancer and cardiovascular disease, inflammatory states associated with malignancies, and/or cardiotoxic effects of cancer therapy. Cancer treatment increases the risk of cardiovascular diseases directly by damaging critical structures of the heart or indirectly by promoting accelerated atherosclerosis. Estimating cardiovascular risk by using advanced imaging and monitoring of the cardiac biomarkers can be used for early detection and treatment of subclinical cardiac injury. Better knowledge of these early and late cardiac effects in cancer patients will enable adoption of both primary and secondary prevention measures of long-term treatment complications in cancer survivors.
引用
收藏
相关论文
共 224 条
[21]  
Sebag IA(2004)5-Fluorouracil induces arterial vasocontractions Ann Oncol 15 661-351
[22]  
Plana JC(2011)Sorafenib-associated multivessel coronary artery vasospasm Herz 36 348-307
[23]  
Demers M(2010)Cardiotoxicity with 5-fluorouracil and capecitabine: more than just vasospastic angina Intern Med J 40 303-297
[24]  
Krause DS(2013)Takotsubo cardiomyopathy and 5-fluorouracil: getting to the heart of the matter Case Rep Oncol Med 2013 206765-539
[25]  
Schatzberg D(2010)Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials Acta Oncol 49 287-611
[26]  
Blann AD(2011)Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML Am J Hematol 86 533-2088
[27]  
Dunmore S(2011)Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia Am J Hematol 86 610-18
[28]  
Goncalves I(2012)Ponatinib in refractory Philadelphia chromosome-positive leukemias N Engl J Med 367 2075-665
[29]  
den Ruijter H(2015)Cardiotoxicity due to chemotherapy: the role of biomarkers Curr Cardiol Rep 17 603-998
[30]  
Nahrendorf M(2007)Radiation-induced cardiovascular diseases: is the epidemiologic evidence compatible with the radiobiologic data? Int J Radiat Oncol Biol Phys 67 10-667
12345678910